Cellular immune response – Page 5 – Communicable Diseases Research

Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection

Article

Published on 2022-09-022022-11-15
Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, 치료제,

Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study

헤르페스 바이러스 감염 및 코로나19 이후 발현: 파일럿 관찰 연구

Observational Study

Published on 2022-09-012022-09-11
Journal: Rheumatology International [Category] COVID19(2023년), SARS, 임상, 치료기술,

[키워드] abnormality accompanied Activation An autoimmune disease Autoimmune Autoimmune disease Cellular immune response clinical and laboratory features CMV complicate contributing to control group controls Course COVID-19 CRP D-dimer detectable Diseases disorders DNA EBV elevated Epstein–Barr virus exaggerate female Fever headache Herpe herpes Herpes virus herpes viruses herpesvirus herpesviruses high mortality high risk Immunocompromised Infection infections laboratory feature liver enzymes male manifestation median age myalgia Numerous Pathologies Patient Reactivation recruited reported rheumatology SARS-CoV-2 severe COVID-19 Spread subject suppressed syndrome temperature the disease Variation variety virus virus infection
[DOI] 10.1007/s00296-022-05146-9 PMC 바로가기 [Article Type] Observational Study

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

Article

Published on 2022-09-012022-11-15
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단,

[키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine the placebo group vaccination Vaccine Volunteer were recorded
[DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기

Humoral and cellular immune response levels at a 1-year follow-up after mild COVID-19

가벼운 COVID-19 이후 1년 추적 관찰에서 체액 및 세포 면역 반응 수준

Article

Published on 2022-09-012022-09-11
Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] antibody antibody levels cellular Cellular immune response COVID-19 detectable disease Follow-up IFN-γ immune response memory Mild mild COVID-19 Participants Patient Primary infection resolved SARS-CoV-2 T cells T-cell T-cell immune response.
[DOI] 10.1016/j.jcv.2022.105236 PMC 바로가기 [Article Type] Article

Short and long-term immune changes in different severity groups of COVID-19 disease

Multicenter Study

Published on 2022-09-012023-07-10
Journal: International Journal of Infectious Diseases [Category] COVID19(2023년),

[키워드] Adaptive immunity Cellular immune response COVID-19 immunology T cells
[DOI] 10.1016/j.ijid.2022.07.026 PMC 바로가기 [Article Type] Multicenter Study

SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV

HIV에 감염된 COVID-19 회복기 개인의 SARS-CoV-2 체액성 및 세포성 면역 반응

Comment

Published on 2022-09-012022-09-12
Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] Abstract Antibody responses Cellular immune response Cellular responses convalescent individual COVID-19 COVID-19,SARS-CoV-2 HIV HIV/SARS-CoV-2 coinfection humoral Humoral immunity Immunity SARS-CoV-2 with HIV
[DOI] 10.1016/j.jinf.2022.05.026 PMC 바로가기 [Article Type] Comment

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination

Article

Published on 2022-09-012022-11-15
Journal: RMD Open [Category] SARS, 진단,

[키워드] activated Activation antibody Autoimmune Autoimmune diseases Cellular immune response cellular response Combination correlated COVID-19 COVID-19 vaccination csDMARD cytokine cytokine profile drug drugs evaluated female first vaccination Frequency Heterologous highest humoral IgG immunosuppressive immunosuppressive therapy Inflammatory inhibitor investigated majority marker median age medications methotrexate monotherapy mRNA-based vaccine MTX Neutralising Antibodies neutralising antibody no difference not significant outcome Patient psoriatic arthritis quantification receiving rheumatic disease rheumatoid arthritis SARS-CoV-2 second vaccination Seroconversion spike-protein spondyloarthritis T-cell T-cell immunity T-lymphocyte T-lymphocyte subsets Therapies therapy titre treated vaccination
[DOI] 10.1136/rmdopen-2022-002293 PMC 바로가기

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod

Article

Published on 2022-09-012022-11-15
Journal: Journal of neurology, neurosurgery, and psychiatry [Category] COVID19(2023년), SARS, 진단,

[키워드] absence Acetate Alter analysed antagonist approved Autoimmune diseases B cell B cells booster booster vaccinations CD4 Cellular immune response clinical neurology elicit elicited fumarate functional immune response healthy individual homologous humoral humoral immune response IgG Immune cell immunogenic immunology Infection Infectious diseases investigated lack Measures mRNA mRNA vaccination mRNA vaccine multiple sclerosis Neutralising activity Patient patients Peripheral blood prospective cohort study Protective receiving receptor Receptor binding reduced risk SARS-CoV-2 serum severe COVID-19 severe SARS-CoV-2 stability T cell T cell response T cell responses therapy these cell Treatment vaccination Vaccinations vaccine-specific antibodies
[DOI] 10.1136/jnnp-2022-329395 PMC 바로가기

Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses

Article

Published on 2022-08-312022-11-15
Journal: Microbiology Spectrum [Category] SARS, 진단, 치료기술,

[키워드] Abbott acute respiratory syndrome Affect affected affecting age age and sex analyzed anti-SARS-CoV-2 antibody Antibody detection BAU binding antibody unit BNT162b2 cellular Cellular immune response cellular immune responses ChAdOx1 nCoV-19 coronavirus correlation Cutoff demonstrated determine Effect Elecsy evaluated Factor female first vaccination Genscript group humoral humoral immune responses immune immune response immune responses interferon gamma investigated male mix-and-match vaccine mRNA mRNA vaccine mRNA-1273 neutralizing antibody predict Qiagen QuantiFERON RBD regimen regimens relationship response robust Roche SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 neutralization second vaccination Sex subject T cell response T cell responses the receptor-binding domain vaccination Vaccine vaccine group vector vector vaccine venous blood was collected were used
[DOI] 10.1128/spectrum.02495-21 PMC 바로가기

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination

Article

Published on 2022-08-312022-11-15
Journal: Frontiers in Immunology [Category] SARS, 변종, 진단,

[키워드] alteration anti-CD20 anti-CD20 therapy antibody applied approach B cell caused CD4 Cellular immune response cellular immunity characterized Complete decrease Delta disorder dosage Effect elicit Frequency healthy controls humoral humoral immune response immune Immune cell immune cells immune response Immunosuppression implication information investigated mean treatment duration Multiple multiple sclerosis neutralization capacity Ofatumumab ofatumumab. omicron pandemic Patient preserved Regulatory T cell SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 variant sclerosis subcutaneously subpopulation sustained T cell T cell response T helper Th1 titer treated treated patient Treatment Tregs vaccination was impaired wild type
[DOI] 10.3389/fimmu.2022.980526 PMC 바로가기